Endocrine Month in Review: November 2021
Editor's note: Clicking in the center of a slide will redirect you to that article or video.
Top Stories of November
- International Osteoporosis Foundation Issues Review of Links Between Bone Loss and Vascular Calcification
The latest review from the International Osteoporosis Foundation is a 14-page document with more than 100 references outlining current data related to the pathophysiological links between vascular calcification and bone loss. - Dapagliflozin Slows Rate of Kidney Function Decline, Regardless of Diabetes Status
Data from a prespecified analysis of DAPA-CKD presented at Kidney Week 2021 provides insight into the effects of dapagliflozin use on the rate of kidney function decline based on the presence of type 2 diabetes from the trial. - Diabetes Community Celebrates Build Back Better Act, Potential for $35 Insulin Caps
Diana Isaacs, PharmD, discusses the Build Back Better Act, the potential impact of a monthly spending cap on insulin, and reflects on the progress that has been made in regard to insulin affordability during the 100-year anniversary of the discovery of insulin. - CLICK Trial: Chlorthalidone Reduces BP in Chronic Kidney Disease and Uncontrolled Hypertension
Data from the CLICK trial presented at Kidney Week 2021 demonstrates chlorthalidone reduced systolic blood pressure by 11 mmHg over a 12-week treatment period among a patient population with stage 4 CKD and uncontrolled hypertension. - Patients with Diabetes Less Likely to Recognize, Report AFib Symptoms
Data from the SWISS-AF study is providing clinicians with insight into the likelihood of patients to perceive symptoms of atrial fibrillation based on whether or not they had diabetes. - Finerenone Could Reduce Progression to Dialysis in Type 2 Diabetes and CKD
An analysis of secondary end points from FIGARO-DKD presented at Kidney Week 2021 provides further insight into the effects of finerenone on kidney outcomes, including a 36% reduction in need for dialysis.
